T0	Participants 70 114	pulmonary arterial hypertension in children.
T1	Participants 340 349	children.
T2	Participants 496 514	children with PAH.
T3	Participants 543 615	29 children treated with inhaled treprostinil for â‰¥6 weeks was performed
T4	Participants 995 1008	in 4 patients
T5	Participants 1677 1709	targeted PAH therapy in children
T6	Participants 1821 1857	warranted in pediatric patients with